Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2007-06-12
2007-06-12
Yaen, Christopher H. (Department: 1643)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
Reexamination Certificate
active
10223880
ABSTRACT:
This invention relates to novel humanized and other recombinant or engineered antibodies or monoclonal antibodies to the vitronectin αvβ3receptor and to the genes encoding same. Such antibodies are useful for the therapeutic and/or prophylactic treatment of αvβ3-mediated disorders, such as restenosis, in human patients.
REFERENCES:
patent: 6160099 (2000-12-01), Jonak et al.
patent: WO 89/05155 (1989-06-01), None
patent: WO 93/20229 (1993-10-01), None
patent: WO 95/25543 (1995-09-01), None
Rudikoff et al (Proc Natl Acad Sci USA 1982 vol. 79 p. 1979.
Riechmann et al., “Reshaping Human Antibodies for Therapy”,Nature. vol. 332, pp. 323-327 (1988).
Johanson Kyung O
Jonak Zdenka L
Taylor Alexander
Gimmi Edward R.
Kinzig Charles M.
Lockenour Andrea V.
SmithKline Beecham Corporation
Yaen Christopher H.
LandOfFree
Anti-alphabeta3 humanized monoclonal antibodies does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Anti-alphabeta3 humanized monoclonal antibodies, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anti-alphabeta3 humanized monoclonal antibodies will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3863205